TIDMSTX

RNS Number : 1285D

Shield Therapeutics PLC

29 January 2018

Shield Therapeutics plc

("Shield" or the "Group")

Notice of Results

London, UK, 29 January 2018: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs, with an initial focus on addressing anaemia associated with renal and gastrointestinal disorders, announces it will report its results for the year ended 31 December 2017 on Wednesday, 28 February 2018.

Carl Sterritt, Chief Executive Officer and Karl Keegan, Chief Financial Officer, will host a presentation and conference call for analysts at 9.30 a.m. GMT on the morning of the results in the Guildhall Room at 85 Gresham Street, London EC2V 7NQ.

-Ends-

For further information please contact:

 
                                       +44 (0) 207 186 
 Shield Therapeutics plc                8500 
 Karl Keegan, Chief Financial 
  Officer 
  Fleur Wood, Director, Investor 
  Relations 
 Nominated Adviser and Joint           +44 (0)20 3100 
  Broker                                2222 
 Liberum Capital Limited 
 Christopher Britton/Steve Pearce 
                                       + 44 (0)20 7418 
 Joint Broker                           8900 
 Peel Hunt LLP 
 James Steel/Christopher Golden 
                                       +44 (0)203 709 
 Financial PR Adviser                   5700 
 Consilium Strategic Communications    shieldtherapeutics@consilium-comms.com 
  Mary-Jane Elliott/Matthew Neal 
 US Investor Relations                 +1 (212) 867 1762 
 Lazar Partners 
 Fern Lazar/David Carey

About Shield Therapeutics plc

Shield is a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru(R), for the treatment of IDA in adult patients with IBD which has exclusive IP rights until the mid-2030's. For more information please visit www.shieldtherapeutics.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORDBGDBGGDBGII

(END) Dow Jones Newswires

January 29, 2018 02:00 ET (07:00 GMT)

Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Shield Therapeutics Charts.
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Shield Therapeutics Charts.